262 related articles for article (PubMed ID: 20521870)
21. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
Hale M; Khan A; Kutch M; Li S
Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
[TBL] [Abstract][Full Text] [Related]
22. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
[TBL] [Abstract][Full Text] [Related]
23. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain.
Katz N; Kopecky EA; O'Connor M; Brown RH; Fleming AB
Pain; 2015 Dec; 156(12):2458-2467. PubMed ID: 26262828
[TBL] [Abstract][Full Text] [Related]
24. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
Rauck RL; Bookbinder SA; Bunker TR; Alftine CD; Ghalie R; Negro-Vilar A; de Jong E; Gershon S
J Opioid Manag; 2006; 2(3):155-66. PubMed ID: 17319449
[TBL] [Abstract][Full Text] [Related]
25. An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
Nalamachu S; deLeon-Casasola OA; Robinson CY; Galer BS; Gould E; Gammaitoni A
Pain Med; 2015 Dec; 16(12):2338-43. PubMed ID: 26301791
[TBL] [Abstract][Full Text] [Related]
26. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
27. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
28. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
[TBL] [Abstract][Full Text] [Related]
29. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
Hale ME; Ma Y; Malamut R
J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
[TBL] [Abstract][Full Text] [Related]
30. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
[TBL] [Abstract][Full Text] [Related]
31. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of morning vs. evening dosing of extended-release hydromorphone on sleep physiology in patients with low back pain: a pilot study.
Webster LR; Smith MD; Mackin S; Iverson M
Pain Med; 2015 Mar; 16(3):460-71. PubMed ID: 25279807
[TBL] [Abstract][Full Text] [Related]
33. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
34. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.
Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
Int J Clin Pract; 2007 Oct; 61(10):1671-6. PubMed ID: 17877652
[TBL] [Abstract][Full Text] [Related]
35. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review.
Sloan PA; Barkin RL
J Opioid Manag; 2008; 4(3):131-44. PubMed ID: 18717508
[TBL] [Abstract][Full Text] [Related]
36. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study.
McIlwain H; Ahdieh H
Am J Ther; 2005; 12(2):106-12. PubMed ID: 15767827
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
[TBL] [Abstract][Full Text] [Related]
38. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
[TBL] [Abstract][Full Text] [Related]
39. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty.
Ahdieh H; Ma T; Babul N; Lee D
J Clin Pharmacol; 2004 Jul; 44(7):767-76. PubMed ID: 15199081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]